MagSense® Technology

Lives Affected by Cancer
0 in 3
Diagnosed with Cancer
0 million
Deaths Caused by cancer
0 million

A Clear Unmet Global Medical Need

Every year cancer kills more than 9 million people globally. And each year billions of dollars are wasted and patients’ outcomes are compromised due to limitations in diagnostic imaging.

Our mission is to change the way we look at cancer, launching the next generation of molecular imaging. Today‘s gold standard provides limited information and visibility resulting in late diagnosis when tumors have grown big enough to be detectable, which is often too late.

MagSense® Imaging Agent Technology can change that.

MagSense Technology Applications

A Look Inside MagSense® Imaging Agent Technology

The MagSense® Imaging Agent Technology utilizes properties of our proprietary PrecisionMRX® Superparamagnetic Iron Oxide Nanoparticles (SPIONs) at its core. Layering biocompatible polymer coatings enhances bioavailability, and tunable polymer coatings allow optimization of factors like bioavailability, immune response, and targetability. Specificity is achieved through the conjugation of targeting molecules, supported by a range of chemistries for drug-loading and biomolecular targeting, including proteins, peptides, and small molecules.

Magnetite Nanoparticle Core

Discreet control of uniformly sized Superparamagnetic Iron Oxide Nanoparticles (SPIONs)- Fe3O4.

Protective Polymer Coating

Range of biocompatible coatings to improve vary bioavailability and provide stability in physiologic conditions.

Stealth Coating – PolyEthylene Glycol

Minimizes opsonization in biological applications.

Targeting Moieties

Antibodies, peptides or cancer specific small molecules provides specificity for targeting tumor cells.

How does MagSense® Imaging Agent Technology Work?

MagSense® nanoparticles result in unique and differentiable image contrast when imaged by MRI.

Bio-safe magnetic nanoparticles are attracted to the tumor and detected.

Play Video

Click video above to watch

1. Inject

Patients are given a low-dose injection of MagSense® imaging agent nanoparticles.

2. Target

Targeting molecules affixed to the nanoparticles, ensure high specificity for the cancer, and cause the nanoparticles to find and bind to tumor cells.

3. Bind

Tumor binding makes MagSense® nanoparticles’ superparamagnetism detectable for MRI imaging resulting in a unique image contrast, well differentiated from nontumor-containing tissue contrast.

4. Clear

MagSense® nanoparticles are safely cleared by the liver where the iron core is metabolized to ferritin in the hemoglobin production pathway.
MagSense® nanoparticles are directed to the tumor and ‘sense’ MRI magnetism on tumor binding.

Diagnostic Imaging is Fundamental in Precision Oncology

Most cancers are asymptomatic, growing unnoticed and undetected until the tumor has grown large enough (many millions of cells) to cause identifiable symptoms. Despite advances made in medical imaging technologies, today’s gold standard still fails to detect small and / or metastatic tumors. Additionally, current medical imaging methods cannot distinguish between benign growths and malignant cancers. This results in missed cancers, intrusive biopsies and surgeries, unnecessary treatment, and needless patient anxiety.

In this era of ever-improving precision oncology, Imagion Biosystems’ molecular MRI may provide novel insights into the presence and extent of disease, helping clinicians and patients optimize treatment plans and extend lives.

While newer blood-based testing, such as the detection of circulating tumor cells or nucleic acids, may provide earlier identification of the presence of cancer, such blood-based testing will necessitate a complementary technology to locate and stage the disease.

Currently, there are five different ways to image the body

How is MagSense® technology better than other imaging methods?

MagSense® technology does not use ionizing radiation, radioactive tracers, or strong magnetic fields. Unlike existing imaging methods that can only identify a “region of interest” and cannot differentiate benign cells from malignant, MagSense® nanoparticles are designed to be a detectable and differentiated image contrast for molecular MRI.

Make sense with MagSense®

Pre and post-dose comparison using MagSense® nanoparticles as the imaging agent in an axillary lymph node scan, to confirm if HER2+ breast cancer has metastasized.


Enlarged, ovoid axillary lymph node

Tumor Involved?

Homogeneous Hypointensity by Normal Lymph Nodes

Heterogeneous Hypointensity in Suspicious Lymph Nodes


Enlarged axillary lymph node with replacement of the normal fatty hilum

Tumor Involved?


Uniformly darkened lymph node suggests



Heterogenous hypointensity and slightly darkened cortex confirms

Metastatic disease

MagSense® Fits Within Current Clinical Workflows

MagSense® nanoparticles work within current standard cancer diagnosis and routine clinical assessment protocols by delivering molecular discrimination with conventional MRI instruments

Learn more about our MagSense® applications and product pipeline

Or if you’re looking to become a strategic partner to help design and drive clinical development, learn more about our collaboration opportunities.